Biotechnology stocks were strong today on the back of Roche's $8.3 billion buyout of InterMune announced Sunday evening. InterMune has their drug pirfenidone for a deadly disease called pulmonary fibrosis.
From the chart above ACAD is up 14% in the month of August alone. Biotech and the S&P 500 are also experiencing a strong month as well. Thank you for reading.
No comments:
Post a Comment